Experiments in mice and human cells shed light on best way
to deliver nanoparticle therapy for cancer

26th March 2020by admin0

Researchers in the cancer nanomedicine community
debate whether use of tiny structures, called nanoparticles, can
best deliver drug therapy to tumors passively—allowing the
nanoparticles to diffuse into tumors and become held in place, or
actively—adding a targeted anti-cancer molecule to bind to specific
cancer cell receptors and, in theory, keep the nanoparticle in the
tumor longer. Now, new research on human and mouse tumors in mice
by investigators at the Johns Hopkins Kimmel Cancer Center suggests
the question is even more complicated.

Leave a Reply

Your email address will not be published. Required fields are marked *

https://nfusion-tech.com/wp-content/uploads/2019/10/Logo_newfusion-footer.png
https://nfusion-tech.com/wp-content/uploads/2019/10/Logo_newfusion-footer.png
Subscribe

If you wish to receive our latest news in your email box, just subscribe to our newsletter. We won’t spam you, we promise!

    New Fusion

    The New Fusion technology is based on a phenomenon called triplet-triplet annihilation (TTA) which is a process in which two triplet excitons annihilate and produce a higher energy singlet exciton.

    Subscribe

    If you wish to receive our latest news in your email box, just subscribe to our newsletter. We won’t spam you, we promise!

      New Fusion

      The New Fusion technology is based on a phenomenon called triplet-triplet annihilation (TTA) which is a process in which two triplet excitons annihilate and produce a higher energy singlet exciton.

      Copyright ©2024 New Fusion All Rights Reserved

      Designed by FallingBrick